Hongqi Pharmaceutical
HONGQI PHARMACEUTICAL
Cherish life, pay attention to health.
CHERISH LIFE CARE ABOUT HEALTH
Major good news! Shenyang Hongqi Pharmaceutical’s Puruini® PutoMani tablets have successfully arrived in China, making the WHO‑preferred 6BPaL regimen immediately available!
Category:
Company News
Author:
Source:
Add time:2025-03-09 11:03
After months of international collaboration, the globally innovative anti-tuberculosis drug Pretomanid (Pretomanid) officially arrived at Shenyang Hongqi Pharmaceutical Co., Ltd. on March 7, 2025. Effective immediately, patients with drug-resistant tuberculosis across China can apply for treatment through authorized channels, marking the official entry of China’s treatment for drug-resistant tuberculosis into a new era of short-course regimens lasting just six months.
Pretomanid, a groundbreaking drug in the global fight against tuberculosis, has been incorporated into the BPaL regimen—the WHO‑recommended first‑line treatment for drug‑resistant TB. Its introduction to China not only exemplifies successful international pharmaceutical collaboration but also reflects the collective wisdom and unwavering commitment of China’s public health system and Hongqi Pharmaceutical, embodying “China’s speed” from regulatory approval to the supply of original‑research‑based imported medicines and ensuring access for Chinese patients. Across India’s cross‑border logistics, every step was coordinated through the concerted efforts of multiple stakeholders, with Shenyang Hongqi Pharmaceutical’s emergency response team providing end‑to‑end support. In this relay race against drug resistance, we outpaced time, helping to advance the WHO’s strategic vision of ending tuberculosis by 2035.
The BPaL regimen has impressed the international community with its groundbreaking efficacy:
1. Short-range
It features a unique multi‑mechanism of action, exhibiting both bactericidal and bacteriostatic activity, and is incorporated into a 6‑month short‑course treatment regimen alongside BDQ and LZD1–3.
2. Potent
The treatment efficacy exceeds 90%, with a median time to negative conversion of 6 weeks, a relapse rate approaching 0%, and a significant reduction in the incidence of BDQ resistance.
3. Safety
BPaL 600 mg demonstrated generally good tolerability and a superior safety profile compared with the standard regimen, with a discontinuation rate due to adverse events of only 2.2%4–5.
4. Highly recommended by the guidebook
Multiple authoritative guidelines and consensus statements, both domestically and internationally, unanimously recommend the BPaL/M regimen as the first-line treatment for drug-resistant tuberculosis6–8.
The emergency medication channel is now open!
To all units at every level:
You can log in via the official website of the Chinese Anti-Tuberculosis Association, access the Information Platform of the Chinese Anti-Tuberculosis Association’s Coordination and Reserve Bank for Anti-Tuberculosis Drugs, and submit your information to apply quickly.
Log in to the Reserve Warehouse Online Information Platform at http://cbk.hongqipharma.com:8096/Default.html and submit your drug application according to the operating instructions.
Patients with drug resistance:
Submit a medication request to the attending physician at the designated hospital, accompanied by the drug resistance test report.
As a leading national pharmaceutical enterprise, Hongqi Pharmaceutical has, for 60 years, remained committed to the mission of “freeing humanity from the burden of tuberculosis” and the vision of becoming an internationally first‑class manufacturer of anti‑tuberculosis drugs. The company continues to invest deeply in scientific innovation and pharmaceutical R&D, placing patients at the center of its efforts and providing comprehensive support to China’s tuberculosis prevention and control initiatives.
References:
1. Stancil SL, et al., Drug Design, Development and Therapy, 2021 Jun 28:15:2815-2830
2. Linkoping University Electronic Press* 2016.
3. Abrahams KA, et al., Nat Commun. 2023 Jun 28;14(1):3828.
4. N Engl J Med. 2022 Sep 1;387(9):810-823.
5. Nyang'wa BT, et al. N Engl J Med, 2022 Dec 22;387(25):2331-2343.
6. Chinese Journal of Tuberculosis, 2019, 41(10): 1025–1073.
7.https://www.who.int/publications/i/item/9789240063129.
8.http://39.106.58.87:8080/standFile/fc63891f84674c228f87c2efc01fa941.pdf.
